Galvin, Gaustad & Stein, LLC Vertex Pharmaceuticals Inc Transaction History
Galvin, Gaustad & Stein, LLC
- $1.15 Billion
- Q3 2025
A detailed history of Galvin, Gaustad & Stein, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Galvin, Gaustad & Stein, LLC holds 33,142 shares of VRTX stock, worth $14.4 Million. This represents 1.13% of its overall portfolio holdings.
Number of Shares
33,142
Previous 22,890
44.79%
Holding current value
$14.4 Million
Previous $10.2 Million
27.37%
% of portfolio
1.13%
Previous 0.92%
Shares
8 transactions
Others Institutions Holding VRTX
# of Institutions
1,786Shares Held
231MCall Options Held
1.83MPut Options Held
1.21M-
Capital World Investors Los Angeles, CA25.9MShares$11.2 Billion1.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA24.2MShares$10.5 Billion0.15% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.25 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA16.6MShares$7.18 Billion1.27% of portfolio
-
State Street Corp Boston, MA11.6MShares$5.04 Billion0.16% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $111B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...